The Avacta (AVCT) share price has halved since May. Can it make a comeback?

The Avacta (LON:AVCT) share price continues to tumble on rising costs, but can it make a comeback? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2021 hasn’t been a particularly great year for the Avacta (LSE:AVCT) share price. Despite reaching a high of 291.8p in May, the stock has since been on a downward trajectory. In fact, over the last five months, it’s down more than 50%. Although looking at a 12-month period, the fall is closer to 25%. Last week, management released its interim report providing an update on the progress being made. So, is this firm about to make a comeback? Or is more decline on the horizon? Let’s take a look.

A year of progress

I’ve previously explored this business. But as a quick reminder, Avacta is a biotech firm that has been actively involved in fighting the pandemic since early 2020. The company’s diagnostics division is currently developing a new generation of lateral flow tests that can detect the Delta variant of Covid-19. Given early data shows higher accuracy than existing tests already on the market, this endeavour could prove lucrative.

Meanwhile, on the therapeutics side of the business, progress for its new chemotherapy drug AVA6000 continues to move forward. In the last six months, the firm received regulatory approval to commence phase one trials. At the same time, its pre|CISION technology, which is being used to develop AVA6000, has been licensed to Point Biopharma. The license is to help create tumour-activated radiopharmaceutical drugs, for which Avacta has received an upfront fee. And it’s on track to continue receiving additional development milestone payments, totalling $9.5m, not including any subsequence royalties if any drug makes it to market.

Should you invest £1,000 in Tesla right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Tesla made the list?

See the 6 stocks

These achievements are certainly commendable in my eyes. And providing the firm can continue progressing at its current speed, its top line could be set to surge – sparking a potential comeback. So why aren’t investors more bullish about this latest report?

The Avacta share price has its risks

The lacklustre share price performance

The latest developments at Avacta have enabled it to expand its revenue stream slightly, with total sales coming in at £2.3m versus £1.8m in 2020. However, like all young biotech companies, it has a lot of expenses to contend with. And it seems, investors were less than pleased to see losses grow bigger.

Research & development costs grew 53%, causing operating losses to jump from £8.1m to £11.3m. Meanwhile, its cash reserves have started depleting. While the firm still has £37m at its disposal, that’s down from £54.5m in 2020.

Drug development is expensive, so this is hardly surprising news. But if the cash burn continues at its current rate, I think it’s likely Avacta will have to raise additional capital either through equity or debt to keep itself afloat. Both of which could have a significant short-term impact on the AVCT share price.

The bottom line

As encouraging as the progress has been, my opinion on this business remains unchanged. There are still a lot of unknowns surrounding this company. And yet it’s boasting a market capitalisation of £310m even with the recent fall in the AVCT share price. That’s nearly 100 times its revenue stream!

In my opinion, the valuation is simply too rich for my tastes. So, Avacta is staying on my watchlist for now.

Should you buy Tesla now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

Is the UK-US trade deal a brilliant buying opportunity for FTSE 100 shares?

A long-awaited trade deal has been struck between the UK and the US, but how much will FTSE 100 stocks…

Read more »

UK supporters with flag
Investing Articles

3 growth stocks up 27% in a month to consider buying now

Stock market volatility has been a brilliant opportunity to buy growth stocks, which are now rebounding at speed. Harvey Jones…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

This FTSE 250 stock has returned over 300% since 2020

After missing out on a 300% return from a FTSE 250 stock five years ago, Stephen Wright is ready for…

Read more »

Investing Articles

Is this one of the most undervalued stocks on the London Stock Exchange?

A market-beating investment manager has just unveiled some of his latest buys from the London Stock Exchange. And this is…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Forget side hustles! This is how I’m building a second income from stocks

Motley Fool analyst Zaven Boyrazian explains his strategy for building a substantial second income in the long run with British…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

The top 4 stocks to buy now and 1 to avoid — according to market experts!

Jefferies experts have highlighted their top picks to profit from surging European defence spending, as well as a company they…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

Looking to invest in the stock market? Here are 3 top picks from the pros to consider

These are some of the highest conviction investment ideas in the UK stock market in 2025 from the team of…

Read more »

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Investing Articles

Could this top UK dividend stock deliver consistent income and wealth for years?

After hiking shareholder dividends for 45 years in a row, this FTSE enterprise has given gargantuan returns to long-term investors.…

Read more »